TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04245397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
Study: NCT03454061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Physical education program (PEP) of 16-week length
Study: NCT04245397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
Study: NCT01982617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study: NCT02818205

Intervention type: OTHER
Intervention: Sensory Challenge Protocol
Description: Measurement of electrodermal activity in response to sensation

Intervention type: OTHER
Intervention: Sensory Challenge Protocol
Description: Measurement of electrodermal activity in response to sensation
Study: NCT04245397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent.
Study: NCT01882634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (Trademark:VScan; Manufacturer:General Electric)
Description: Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
Study: NCT00822510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Interpersonal Counseling
Description: Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
Study: NCT04245397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine is a hypomethylating agent.
Study: NCT00712712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Patient-controlled analgesia (PCA), allowing morphine consumption to be titrated to the patient's needs and thus allowing morphine doses to be adapted to an increase in pain in the patient's post-operative period or a rapid analgesic effect of radiofrequency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Pain notebook will allow the patient to describe the pain specific to the metastasis concerned, containing information on :~* The intensity of the minimum, average and maximum pain of the last 24 months. hours as well as the intensity of the pain of the moment according to a scale 11-point digital,~* the background morphine analgesic treatment during the last 24 hours,~* the morphine analgesic treatment taken during painful attacks,~* the possible undesirable effects of morphine treatment.~* the morphinic, non-morphinic and co-antalgic treatment is noted, as well as that the total dose of oral morphine or oral morphine equivalent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Patients' quality of life will be assessed using the quality of life questionnaire EORTC QLQ-C30 at inclusion in the study and at 8 weeks after radiofrequency. ablation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Recent technique of thermal destruction of tumors.~This technique consists of inserting an electrode needle into the tumour under X-ray or ultrasound guidance or intraoperatively under laparoscopy for example. This needle carries a current or a light wave depending on the characteristics of the generator to which it is connected (radiofrequency, laser).~Radio frequencies are radiation non-ionising electromagnets. In this context of tissue ablathermia wavelengths ranging from 400kHz to 500kHz.
Study: NCT01332669

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DebDox TACE
Description: HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DebDox TACE
Description: HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
Study: NCT00333827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimal therapy for cardiaca failure
Description: optimal therapy for cardiaca failure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell
Description: stem cell
Study: NCT04207606

Intervention type: BEHAVIORAL
Intervention: Post Epidural Steroid Injection Follow-up
Description: All enrolled patients will undergo epidural steroid injection with fluoroscopy per the Spine Intervention Society guidelines as part of their normal care. Patients will then be contacted for survey responses every 3 days for a maximum of 23 days, to assess pain intensity and change.
Study: NCT04390919

Intervention type: OTHER
Intervention: elevated monocyte count
Description: The monocyte count at admission was higher than 0.445×10\*9 cells/L
Study: NCT01114035

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood samples and skin biopsies
Description: to detect mutations

Intervention type: GENETIC
Group type: OTHER
Intervention: Skin biopsies
Description: to detect mutations
Study: NCT02689154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: W8Loss2Go
Description: The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
Study: NCT04656821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Rx
Description: Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Block
Description: Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
Study: NCT00822510

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone delivered education only
Description: Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
Study: NCT04656821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Paravertebral Block
Description: Patients of this group will receive 25 mg bupivacaine 0.5% , plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at desired level under ultrasonography
Study: NCT00086619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic hPTH 1-34
Description: Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic hPTH 1-34
Description: Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
Study: NCT00532454

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: tamoxifen 20mg, PO, QD until disease progression
Study: NCT02290756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Program
Description: The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low cost evidence based toolkit
Description: The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information
Study: NCT02329496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotus Valve and LOTUS Edge Valve System
Description: Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
Study: NCT01986400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer-to-Peer Support Mentoring
Description: The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
Study: NCT02806635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP Online
Study: NCT02773446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Description: ETEC Bacteria
Study: NCT03001856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oblique Intradermal Suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intradermal Suture
Study: NCT03510013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1-1-8 wash-in
Description: wash-in phase during start of low flow anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Drug used for wash-in protocol
Study: NCT01066039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
Study: NCT01902524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-TTS
Description: All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
Study: NCT02290756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low cost evidence based toolkit
Description: The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~1. Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~2. Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information
Study: NCT01772810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human spinal cord stem cells.
Description: Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Study: NCT02996968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-removal
Description: Self-discontinuation of a transurethral catheter
Study: NCT01323400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.
Study: NCT03141931

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
Study: NCT02426125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT04029584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin IV
Description: A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin IV
Description: A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifadin 300Mg Capsule
Description: Rifadin 600mg by mouth as two 300mg rifadin capsules
Study: NCT00981409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium
Description: The dose of Fondaparinux will be determined based on a subject's body weight (\<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; \>100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
Study: NCT04029584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifadin 300Mg Capsule
Description: Rifadin 600mg by mouth as two 300mg rifadin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 MG
Description: one oral dose of fluvastatin (Lescol ) 20mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 MG
Description: one oral dose of fluvastatin (Lescol ) 20mg capsule
Study: NCT02992353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-port pulmonary resection surgery
Description: Three-port pulmonary resection surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-port or two-port surgery
Description: Single-port or two-port pulmonary resection surgery
Study: NCT00639301

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
Study: NCT03192449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole.
Description: Single dose 400mg orally
Study: NCT02861690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Paclitaxel
Description: Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
Study: NCT02564198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT02451657

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study
Study: NCT00208429

Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle Acetabular System
Study: NCT01629628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine
Description: 6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------
Study: NCT00966992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT03658785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL
Description: On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
Study: NCT00981409

Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin (UFH)
Description: UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
Study: NCT01898858

Intervention type: DEVICE
Intervention: Hypercapnia inhalation (Altitrainer NP 190)
Description: Hypercapnia inhalation using an Altitrainer NP 190

Intervention type: DEVICE
Intervention: Hypoxia and hypercapnia (Altitrainer NP 190)
Description: Hypoxia and hypercapnia inhalation using an Altitrainer NP 190

Intervention type: DEVICE
Intervention: Hypoxia inhalation (Altitrainer NP 190)
Description: Hypoxia inhalation using an Altitrainer NP 190
Study: NCT03686137

Intervention type: OTHER
Intervention: Data collection
Description: Colelction of pre-operative, surgical and post-surgical data
Study: NCT00822679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are given placebo for 3 consecutive nights